. Author manuscript; available in PMC: 2016 Jul 12.

Published in final edited form as: Prostate Cancer Prostatic Dis. 2015 Oct 27;19(1):53–56. doi: 10.1038/pcan.2015.49

Table 3.

Odds Ratios for Prostate Cancer Stratified by TMPRSS2:ERG Fusion Status in Relation to Total Duration of Aspirin Use

Duration of Aspirin Use	Controls No (%)	TMPRSS2:ERG Negative No (%)	Age-Adjusted OR (95% CI)	Multivariate OR (95% CI) ^*	TMPRSS2:ERG Positive No (%)	Age-Adjusted OR (95% CI)	Multivariate OR (95% CI) ^*
Never user	457 (49)	90 (51)	1.00 (referent)	1.00 (referent)	108 (63)	1.00 (referent)	1.00 (referent)
0.1 – 2.5 years	127 (14)	21 (12)	0.88 (0.52 – 1.47)	0.79 (0.47 – 1.35)	23 (13)	0.90 (0.54 – 1.49)	0.78 (0.46 – 1.31)
2.6 – 4.9 years	90 (10)	14 (8)	0.80 (0.43 – 1.49)	0.87 (0.46 – 1.64)	12 (7)	0.65 (0.34 – 1.26)	0.65 (0.33 – 1.26)
5.0 – 9.9 years	127 (14)	20 (11)	0.84 (0.49 – 1.44)	0.78 (0.45 – 1.36)	16 (9)	0.65 (0.36 – 1.16)	0.54 (0.30 – 0.98)
>= 10 years	139 (15)	30 (17)	1.21 (0.76 – 1.96)	1.19 (0.73 – 1.95)	12 (7)	0.52 (0.27 – 0.99)	0.46 (0.24 – 0.88)

Adjusted for age, race, family history of prostate cancer, prostate cancer screening within 5 years prior to diagnosis (cases) or referent date (controls)